Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Loxo@Lilly Discovered Novel Jaypirca™ (pirtobrutinib) for Adult Patients

Loxo@Lilly the oncology unit of Eli Lilly and Company discovered novel Jaypirca™ (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

Jaypirca is the first and only BTK inhibitor specifically discovered for patients with mantle cell lymphoma previously treated with a covalent BTK inhibitor.

Jaypirca, a highly selective kinase inhibitor, which uses a novel binding mechanism. Jaypirca has the ability to restore BTK inhibition in MCL in patients who have earlier treated with a covalent BTK inhibitor (ibrutinib, acalabrutinib, or zanubrutinib) and extend the benefit of targeting the BTK pathway. Jaypirca will beocme the new treatment option and brings new hope for people with relapsed or refractory MCL.

Jaypirca (pirtobrutinib, formerly known as LOXO-305) (pronounced jay-pihr-kaa) is a highly selective (300-fold selective for BTK compared to 98% of other kinases tested in preclinical studies), non-covalent (reversible) enzyme. Jaypirca is an oral prescription drug approved as 100 mg or 50 mg tablets taken once daily. 200 mg  with or without food until disease progression or toxicity is unacceptable.

U.S. Food and Drug Administration (FDA) approves Jaypirca™ for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024